References
- Invega®Sustenna®prescribing information2012 Available from: http://www.invegasustenna.com/important-product-informationAccessed November 8, 2012
- GopalSGassmann-MayerCPalumboJSamtaniMNShiwachRAlphsLPractical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophreniaCurr Med Res Opin20102637738720001492
- SamtaniMNGopalSGassmann-MayerCAlphsLaPalumboJDosing and switching strategies for paliperidone palmitate based on population pharmacokinetic modelling and clinical trial dataCNS Drugs20112582984521936586
- Food and Drug Administration, Department of Health and Human ServicesSupplement Approval2012 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/022264Orig1s005ltr.pdfAccessed December 10, 2012
- CoppolaDLiuYGopalSA one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophreniaBMC Psychiatry2012122622455454
- PandinaGLaneRGopalSA double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophreniaProg Neuropsychopharmacol Biol Psychiatry20113521822621092748
- KramerMLitmanRHoughDPaliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety studyInt J Neuropsychopharmacol20101363564719941696
- PandinaGJLindenmayerJPLullJA randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophreniaJ Clin Psychopharmacol20103023524420473057
- De MeulderMRemmerieBMde VriesRValidated LC-MS/MS methods for the determination of risperidone and the enantiomers of 9-hydroxyrisperidone in human plasma and urineJ Chromatogr B Analyt Technol Biomed Life Sci2008870816
- SamtaniMNVermeulenAStuyckensKPopulation pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychoticClin Pharmacokinet20094858560019725593
- CirincioneBRedmanMFiedler-KelleyJLudwigEVermeulenAPopulation pharmacokinetics of paliperidone ER in healthy subjects and patients with schizophreniaPaper presented at the Annual Meeting of the American Society for Clinical Pharmacology and TherapeuticsMarch 21–24, 2007Anaheim, CA
- DuffullSBAaronsLDevelopment of a sequential linked pharmacokinetic and pharmacodynamic simulation model for ivabradine in healthy volunteersEur J Pharm Sci20001027528410838017
- WeidenPJKCGroggALocklearJPartial compliance and risk of rehospitalization among California Medicaid patients with schizophreniaPsychiatr Serv20045588689115292538
- HeringsRMErkensJAIncreased suicide attempt rate among patients interrupting use of atypical antipsychoticsPharmacoepidemiol Drug Saf20031242342412899119
- Ascher-SvanumHZhuBFariesDEThe cost of relapse and the predictors of relapse in the treatment of schizophreniaBMC Psychiatry201010220059765
- GopalSHoughDXuHEfficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response studyInt Clin Psychopharmacol20102524725620389255
- NasrallahHAGopalSGassmann-MayerCA controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophreniaNeuropsychopharmacology2010352072208220555312